Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
One finding from this study was that VTE was more likely to occur at atypical sites in patients with myelofibrosis compared to those without the disease.
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
This study investigated differences in the morbidity and mortality of patients presenting with PV or ET with and without splanchnic vein thrombosis.
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
Research into opioid alternatives for cancer-related pain has stalled, however substance use disorders remain problematic.
The FDA has approved Sarclisa (isatuximab-irfc; Sanofi), in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor.
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
The discovery that tumors in myeloma have immunogenic antigens provides a rationale for the development of neoantigen-based therapeutic vaccines.
